Diabetes mellitus continues to be a major health issue worldwide. Despite all of the treatment options available on the market, many patients with diabetes fail to reach their treatment goals. Novel agents such as the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors show promise in effectively lowering blood glucose. Objective: To review the scientific literature for efficacy information regarding the use of approved SGLT2 inhibitors (canagliflozin, dapagliflozin and empagliflozin) in the treatment of Type 2 Diabetes Mellitus (T2DM). Methods: A MEDLINE (1950-August 2014) literature review was performed. All of the literature published as an original clinical trial was included in this review. Other pertinent articles published related to the original clinical trial were also included. Meta-analysis type studies were not selected for this review. Conclusions: With an increasing prevalence and incidence of type 2 diabetes mellitus worldwide, there is an apparent need for effective therapeutic strategies to combat this chronic and progressive disease. SGLT2 inhibitors offer this potential. Recently approved agents (canagliflozin, dapagliflozin and empagliflozin) have shown significant promise as mono-and add-on therapy to current glucose-lowering regimens that may not otherwise be providing sufficient glycemic control in T2DM patients.
Introduction
Diabetes mellitus continues to be a major health issue worldwide, affecting nearly 26 million adults in the United States. Controlling blood glucose levels is essential in managing symptoms and preventing complications associated with the disease. In 2011, close to 85% of US adults with diabetes reported taking antihyperglycemic medication [1] .
Despite all the treatment options available on the market, many patients with diabetes fail to reach their treatment goals. Most of these medications depend on the presence or action of insulin to exert their therapeutic effect. This can provide little benefit to patients whose disease progression has led to deterioration in pancreatic beta cell function. Additionally, these agents are associated with concerning side effects, including the risk of inducing hypoglycemia [2]- [4] .
A new class of agents has emerged with glycemic control via alternate means, specifically by inhibiting the reabsorption of glucose and increasing its excretion from the kidneys. This novel approach of the Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors shows promise in effectively lowering blood glucose in a noninsulindependent way. Sodium-Glucose Cotransporter 2 inhibitors exert their effect by enhancing renal glycosuria. The extent to which they induce glycosuria is dependent on the plasma glucose concentration. As a result, blood glucose levels cannot be lowered below physiological levels and hence, the risk of hypoglycemia is not concerning [5] . This mechanism of action allows use as monotherapy or in combination with current antidiabetes medications, including insulin therapy [2]- [4] . Sodium-Glucose Cotransporter 2 inhibitors have also been shown to promote weight loss at the same time, either independently or in combination with other antidiabetic agents. However they have a risk of potentially increasing the likelihood of genitourinary tract infections [6] .
The United States Food and Drug Administration (FDA) recently approved three SGLT2 inhibitors, canagliflozin in 2013, dapagliflozin and empagliflozin in 2014. This article discusses the SGLT2 inhibitors as new approaches to managing type 2 diabetes mellitus (T2DM), focusing on the evidence available regarding the efficacy and safety of this emerging class of antidiabetic agents. Canagliflozin, dapagliflozin, and empagliflozin were selected for this review since they are the only agents currently approved by the FDA. Figure 1 illustrates the literature search and selection process details used in the identification of clinical trials for this review. A literature review was performed in MEDLINE (1950-August 2014) using the keywords diabetes mellitus type 2 AND canagliflozin OR dapagliflozin OR empagliflozin. The references identified from the literature review were then evaluated. All of the literature retrieved from MEDLINE that was published as an original clinical trial was included in this review. Other pertinent articles published related to the original clinical trials were also considered. Meta-analysis type studies were not selected for this review. References included in this review were limited to studies conducted in humans and written in the English language. Other pertinent articles published related to the original clinical trial were also included.
Data Sources
Meta-analysis type studies were not selected for this review.
Dapagliflozin
Dapagliflozin, D-glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-, compounded with (2S)-1,2-propanediol, hydrate (1:1:1) [2], was rejected by the FDA in January 2012 due to concerns about the cancer risk seen in studies [17] . However, after reviewing more data on its safety profile, dapagliflozin was approved by the FDA in early 2014. The pharmacokinetic and pharmacodynamic properties of dapagliflozin are similar to canagliflozin. Dapagliflozin can be administered without regard to food. The oral bioavailability of dapagliflozin 10 mg is 78%. Maximum plasma concentration is usually reached within two hours in a fasting state and administration with a high-fat meal decreases the C max by up to 50% without altering the AUC, but is not clinically significant. The terminal half-life is approximately 12.9 hours following a dose of 10 mg. Dapag- liflozin is 91% protein bound, which is unchanged in patients with renal or hepatic impairment. It is metabolized primarily by UGT1A9 with minor CYP-activity and is eliminated mainly through the kidneys. At steady state, T2DM patients with mild, moderate, or severe renal impairment (determined by estimated glomerular filtration rate (eGFR)) experience 45% to 3-fold higher systemic exposure of the drug without a corresponding higher 24-hour urinary glucose excretion. The steady state 24-hour urinary glucose excretion is 42% -90% lower in these patients [2]. Dapagliflozin is not recommended in patients with moderate renal impairment as improvement in glycemic control was not seen in this population. Additionally, dapagliflozin is not expected to be effective in patients with severe renal impairment or end stage renal disease (ESRD). Dapagliflozin is contraindicated in these populations along with patients on dialysis. According to Child-Pugh class grading, mild, moderate, and severe hepatic impairment do not warrant dose adjustments with dapagliflozin, but the risk-benefit for use in patients with severe impairment should be individually assessed as the safety and efficacy have not been specifically studied in this population [2] .
Overall, 11 studies assessing the use of dapagliflozin in T2DM were identified ( Table 2 ) [18] - [28] . The majority of trials evaluated the effectiveness of dapagliflozin as add-on therapy to standard treatments [18] [20] [22] [24]- [28] . The time period for the 11 studies ranged from 12 to 102 weeks, and investigators used dapagliflozin doses of 1 -20 mg [18] - [28] . Dapagliflozin consistently showed statistically significant decreases in mean HbA1C (%) compared to control groups [18] - [23] [25] [26] [28] . The largest difference in HbA1C (%) reduction between dapagliflozin and placebo groups was −0.84% after 24 weeks of treatment with dapagliflozin 5 mg [19] . No difference in the adjusted mean change in HbA1C (%) from baseline between the dapagliflozin and glipizide groups was observed in a 52-week study, which concluded that dapagliflozin was statistically noninferior to glipizide [24] . A few trials found a statistically significant difference in patients achieving an HbA1C of <7% at the end of the study period in the dapagliflozin treatment groups compared to placebo [18] - [20] [22] [26] .
The majority of studies found a statistically significant decrease with mean FPG in dapagliflozin treatment groups compared to control groups [18] - [23] [25] [26] [28] . Three of the four studies that assessed 2-h PPG after an oral glucose tolerance test (OGTT) found statistically significant decreases in dapagliflozin groups compared to control groups [19] [25] [26] . Although [27] did not report statistical significance, 2-h PPG was found to be lower in the dapagliflozin groups. All studies found a greater decrease in body weight after treatment with dapagliflozin compared to the control [18] - [28] .
The most common adverse events were diarrhea, headache, nasopharyngitis, upper respiratory tract infection, urinary tract infection, influenza, back pain, hypertension, cough, and arthralgia [18] - [28] . Nine trials documented >55% of subjects experiencing at least one adverse event but <10% of subjects discontinued a study due to an adverse event [18] - [22] [24] [25] [27] [28] . Fewer adverse events overall were reported by [23] (38.9% -53.8%) and [26] (47.3% -51.9%). Of the reported events, approximately 25% or fewer were determined to be drug-related in five trials [18] - [20] [22] [26] . The overall incidence of urinary and genital tract infections was low (<15%), but more common in dapagliflozin groups compared to control groups [18] - [25] [27] [28] . In five of the studies, the events were reported as mild or moderate and responded adequately to treatment [18] - [21] [26]. Among four other trials, there was a total of 12 patients who withdrew from the study because of a UTI or genital infection [24] - [26] [28] .
Hypoglycemic events did not occur frequently (<10%) or severely and were similar to placebo or treatment groups in most studies [18] - [23] [25] . The incidence of hypoglycemia was higher in treatment groups using dapagliflozin with hypoglycemia-associated medications such as insulin (25% -29.2% versus 13% in placebo) [28] , insulin with insulin-sensitizers (53.6% -60.4% versus 51.8% in placebo) [27] and sulfonylureas (6.9% -7.9% versus 4.8% in placebo) [26] . A serious adverse event related to hypoglycemia was also reported for dapagliflozin 5 mg [28] . A significantly higher proportion of patients experienced hypoglycemia on glipizide (40.8%) compared to dapagliflozin (3.5%) with six episodes of hypoglycemia leading to discontinuation in the glipizide group [24] .
Blood pressure was also monitored in trials. Some studies reported that systolic blood pressure was slightly reduced in both dapagliflozin and control groups [18] [27] . Overall, most studies found that dapagliflozin treatment was associated with only a few incidences of hypotension (<5%) [18] - [22] [24] [28] . An incidence of syncope was reported in a patient receiving dapagliflozin 10 mg [26] , while an episode of severe hypotension was noted in a patient on dapagliflozin 5 mg [19] . [29] with a reduction in AUC (16%) and C max (37%) when taken after a high-fat and high-calorie meal. Although reductions in systemic exposure were noted, the impact on clinical outcomes was not deemed significant. As a result, empagliflozin may be taken with or without food. Empagliflozin has a plasma protein binding of roughly 86%. Metabolism occurs primarily via glucuronidation with minimal metabolite exposure. The terminal half-life of empagliflozin is 12.4 hours. Empagliflozin is primarily eliminatedrenally. Increases in AUC have occurred in patients with renal impairment, kidney failure or ESRD. Empagliflozin is contraindicated in severe renal impairment, ESRD, or dialysis [3] .
Empagliflozin
The impact on plasma concentration varies based on the degree of renal and hepatic impairment. Patients with moderate renal impairment, kidney failure, or ESRD have peak plasma concentrations comparable to patients with normal renal function. On the other hand, patients with mild and severe renal impairment have approximately 20% higher peak plasma concentrations. Renal function should be evaluated prior to and throughout empagliflozin treatment. Use of empagliflozin should be avoided in patients with eGFR's of <45 mL/min/ 1.73m 2 . Mild to severe hepatic impairment may also result in AUC and C max elevations, but dose adjustments are not warranted [3] .
Two pivotal trials evaluating the efficacy of empagliflozin in T2DM patients over 12 weeks were identified and summarized in Table 3 . One study [30] assessed empagliflozin as monotherapy and another [31] as add-on therapy to metformin. Doses ranged from 1 mg to 50 mg. Significant reductions in HbA1C, FPG, and weight were observed in the 5 mg, 10 mg, 25 mg, and 50 mg empagliflozin groups when compared to placebo [30] [31] . Both studies reported greater proportions of empagliflozin groups reaching HbA1Cs ≤ 7% compared to placebo (30% -45% of empagliflozin 5 mg and 25 mg versus 22% of placebo [30] and 35.7% -38.0% of empagliflozin 10 mg, 25 mg, and 50 mg versus 15.5% of placebo [31] ). Similar reductions were observed with sitagliptin 100 mg (33.8%) compared to placebo (15.5%) [31] .
Overall, adverse events were similar among empagliflozin, placebo, and open-label agent groups. Pollakiuria, thirst, nasopharyngitis, urinary tract infections, and genital infections were the most common adverse events reported by empagliflozin subjects. Although the incidence of UTIs was comparable among study groups within each trial, an increased number of genital infections occurred in the empagliflozin groups. Hypoglycemic episodes among treatment and placebo groups were not significantly different. Additionally, both studies reported a trend toward a potential dose-related increase in hematocrit in the empagliflozin groups (0.6% -2.5%) [30] [31] . Blood pressure (systolic and diastolic) changes trended toward dose-dependent decreases in the empagliflozin (5 mg, 10 mg, and 25 mg) versus placebo groups but were not statistically significant. The greatest change occurred in the empagliflozin 25 mg group [31] .
Other SGLT2s
Although canagliflozin, dapagliflozin, and empagliflozin are the only SGLT2 inhibitors on the US market, several other candidates are currently in development. These include ipragliflozin, tofogliflozin, and ertugliflozin. 
Conclusion
Considering the increasing prevalence and incidence of type 2 diabetes mellitus worldwide, there is an obvious need for effective therapeutic strategies to combat this chronic and progressive disease. The need for agents with novel mechanisms of action is becoming more and more crucial owing to the need for individualized glycemic targets and glucose-lowering therapies, concerning side effects of many current therapies, and the progressive β-cell function decline associated with T2DM. SGLT2 inhibitors offer this potential and recently approved canagliflozin, dapagliflozin, and empagliflozin have shown significant promise as mono-and add-on therapy to current glucose-lowering regimens that may not otherwise be providing sufficient glycemic control in T2DM patients. Short-term benefits have certainly been made clear through the variety of clinical trials performed on these drugs, however there is still a need to establish long-term safety and efficacy. The significance of the unique side effects of increased genital mycotic infections and associated adverse events must also be considered. Several other agents in this class are in phase III trials and show similar promise in their efficacy as addon treatments.
